OPR - Delayed Quote USD

JNJ Sep 2024 162.500 call (JNJ240927C00162500)

0.0100

-0.2700

(-96.43%)

As of September 27 at 3:53 PM EDT. Market Open.

Key Events

Advanced Chart

Loading Chart for JNJ240927C00162500

9/21 12:03 PM

DELL

Previous Close 0.2800
Open 0.2800
Bid 0.0000
Ask 0.0100
Strike 162.50
Expire Date 2024-09-27
Day's Range 0.0100 - 0.9500
Contract Range --
Volume 2,770
Open Interest 1.7k

Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma

CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma

DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned

Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

$Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease$

Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease

$TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma$

TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

JNJ Sep 2024 162.500 call (JNJ240927C00162500)

0.00%

-99.68%

-99.68%

-99.68%

-99.68%

-99.68%

-99.68%

Recent News: JNJ

Legend Biotech's J&J-Partnered Drug Cut The Risk Of Death By 45% In Multiple Myeloma

CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line

DARZALEX® (daratumumab)-based maintenance regimens show clinically meaningful deep and durable responses in transplant-eligible patients with newly diagnosed multiple myeloma

DARZALEX FASPRO®-based quadruplet regimen significantly improves minimal residual disease negativity for newly diagnosed multiple myeloma patients for whom transplant is not planned

Johnson & Johnson Reports Updated Data From Two Early-Stage Multiple Myeloma Studies Of Talvey Combo Treatment

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

Novel combination of TALVEY® (talquetamab-tgvs) and TECVAYLI® (teclistamab-cqyv) suggests high response rates and durable responses in triple-class refractory patients with relapsed or refractory multiple myeloma, including those with extramedullary disease

TALVEY® (talquetamab-tgvs) and DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) based combination shows deep and durable responses in patients with relapsed or refractory multiple myeloma

Is Johnson & Johnson (JNJ) the Best Stock To Buy Right Now According To Billionaire Cliff Asness?

Johnson & Johnson (JNJ): Leveraging Innovation for Sustained Market Leadership

Johnson & Johnson (JNJ): A Good Undervalued Blue Chip Stock to Buy According to Analysts

Johnson & Johnson (JNJ): A Good Holding Company Stock to Buy Now

Date
Close
Open
High
Low
Volume